🧭 MACRO SNAPSHOT

The tape is stretched but constructive. S&P at 7,499 with VIX at 17.65 tells you complacency is creeping back in after the Iran-driven vol spike earlier this quarter. Fed funds at 3.63% and the 10Y at 4.38% (2Y at 4.10%) leaves us with a mildly positive curve — the yield curve inversion regime is behind us, but real rates remain restrictive enough that duration-sensitive names (solar, small-cap industrials, unprofitable growth) continue to underperform on any macro wobble. HY credit spreads at 280bps are tight — not extreme, but leaving little cushion if earnings disappoint. Unemployment at 4.3% continues the slow drift higher; this is the number I'm watching most closely for signs the Fed accelerates cuts.

Two sector-relevant crosscurrents for the book: (1) Oil is set for a steep monthly drop as Trump/Iran signal talks in Qatar (CNBC) — bearish for energy equities near-term but relieves input-cost pressure on data center buildouts and manufacturing. (2) Medicare will begin covering GLP-1s for obesity (CNBC) — a genuine step-change for $LLY and Novo, and one reason today's rolling review on Lilly matters. The AI capex debate is heating up (Axios: "AI boom's historical warning"; BlackRock flagging trades "beyond Nvidia") — this is exactly the market noise long-horizon investors should be filtering, but it's worth knowing bear narratives are gaining share of voice.

₿ BITCOIN DAILY WRITE-UP

Price & Market Structure: BTC at $58,580, down 0.98% on the day, -6.09% on the week, -19.38% on the month. We are now ~54% below the ATH and roughly 14 months post-halving — historically the window where cycle peaks should be forming, not deepening drawdowns. Dominance at 55.4% suggests capital is consolidating into BTC vs. alts, which is typical late-cycle behavior.

Structural Thesis: Bitcoin remains a long-duration, non-sovereign store of value with a fixed supply schedule and an accelerating institutional/corporate treasury adoption curve. The reason to hold is not the four-year cycle — it's the multi-decade thesis that fiat debasement + regulatory acceptance + corporate balance sheet adoption creates a structurally rising price floor over time.

What Happened This Week: Two material developments. First, CryptoQuant's Apparent Demand metric has now been negative for 208 consecutive days — historically a regime-change signal, not a mid-cycle wobble. Second, corporate BTC treasury holdings have doubled since 2025 to ~5% of total supply (Crypto Briefing, 6/27), which is a real structural offset. Trump also disclosed $50M+ in self-custodied BTC (Bitcoin Magazine) — noise, but noise that shifts the political backdrop favorably.

Bull / Bear Scorecard:

Bull:
- Corporate treasuries now hold ~5% of supply and doubled in 18 months — permanent, price-insensitive demand sink that didn't exist in prior cycles
- Post-halving supply squeeze intact: 95.47% mined, new issuance at all-time lows
- Institutional infrastructure (Anchorage/Binance off-exchange settlement) continues to build regardless of price

Bear:
- 208 days of negative apparent demand — most important signal on the board. Historical precedent is bear regime, not consolidation.
- Cycle position at 14mo post-halving, 54% below ATH — either the cycle peaked early or the four-year pattern is broken
- BTC is behaving like a risk asset in a tightening real-rate world; macro tailwinds absent

Conviction Check: Action: HOLD | Conviction: 4/10. Conviction unchanged from last week. The structural deterioration is real, but I don't add or trim on price alone — the multi-year thesis requires patience through drawdowns of exactly this shape.

What to Watch:
- Apparent Demand metric flipping positive and holding for 30+ days — single most important structural tell
- Sustained spot ETF net inflows of $500M+/week
- Any move by the Fed to cut aggressively (would revive the debasement trade)

Community Pulse: Reddit was dark today — no threads surfaced across tracked communities, which is itself a signal (fear/apathy vs. euphoria). The Bitcoin Layer is running two pieces on whether their liquidity indicator is broken and noting BTC is "breaking support lines left and right" — the tone from the more sophisticated newsletters is cautious-to-bearish on price, thoughtful-to-bullish on the multi-year setup. Sentiment is at capitulation-adjacent levels, which is uncomfortable but historically not a bad time to be patient.

🔬 TODAY'S DEEP DIVES

LLY — Eli Lilly and Company — ROLLING REVIEW
Conviction: 5/10 | Status: WATCHLIST | Sector: Healthcare

WHAT THEY DO: Eli Lilly is a global pharmaceutical company that discovers, manufactures, and markets prescription drugs. Their revenue engine right now is the incretin franchise — Mounjaro (type 2 diabetes) and Zepbound (obesity), both branded versions of tirzepatide, a GLP-1/GIP dual agonist. They sell to health systems, PBMs, insurers, and government programs; patients are the users, but the payors are institutional.

WHY IT'S INTERESTING NOW: Two things. First, Medicare will begin covering obesity drugs for the first time (CNBC today) — a genuine step-change in the addressable market for Zepbound. Second, the stock has ripped ~24% since my last review (from $967 to $1,199), which has erased the valuation compression that made the April setup interesting. TTM revenue growth has re-accelerated to 55.5% (from mid-30s), but forward P/E has re-expanded to ~27x. The setup has shifted from "great business at a fair price" to "great business, market caught up."

BULL CASE:
- Medicare obesity coverage is a real TAM expansion — millions of new eligible patients enter the funnel
- Tirzepatide is best-in-class on efficacy (weight loss %) vs. semaglutide; pipeline includes oral orforglipron (Phase 3), which could unlock a huge non-injectable market
- Manufacturing capacity build-out addresses the supply constraint that has capped revenue for two years — as supply catches up, revenue converts more efficiently

BEAR CASE:
- At ~27x forward earnings and $1,199, much of the good news is priced in — you're paying for perfection
- GLP-1 competition intensifying: Novo's next-gen candidates, Amgen's MariTide, Viking Therapeutics — the moat is real but not permanent
- Regulatory/pricing risk: Medicare coverage comes with negotiation exposure via the IRA — a double-edged sword

KEY METRICS: Revenue growth 55.5% TTM; forward P/E ~27x; operating margins expanding as scale kicks in; differentiator is incretin efficacy leadership + oral pipeline optionality.

BOTTOM LINE: Excellent business, but the setup has moved from asymmetric to fairly-valued — hold at 5/10 on the watchlist and wait for either a pullback to the $1,000-1,050 range or a pipeline catalyst before upgrading.

No new ideas were screened today, so the deep dive section is limited to the LLY rolling review.

📋 TARGET LIST STATUS

No new names added today; no names displaced today. $LLY was rolled through the deep review queue and downgraded from prior 7/10 to 5/10 as valuation has re-rated. $MELI was abandoned earlier in the week at 5/10 — didn't meet the conviction bar to hold a spot.

💼 YOUR PORTFOLIO

• AAPL | HOLD | 5/10 — Price deteriorating on renewed AI skepticism and tariff/price-hike concerns. Thesis intact but conviction subdued; no action.
• AVAV | HOLD | 3/10 — Fresh 52-week lows, $89M charge disclosed, class action noise. This is the weakest link in the book — actively watching for a fundamental reason to trim.
• AVGO | BUY MORE | 9/10 — Down 7.9% in a week on the semi sell-off; thesis fully intact (custom silicon + VMware). Valuation improved. Highest conviction add in the book.
• BABA | STRONG HOLD | 6/10 — Near 52W low, -50.7% from high. Anthropic distillation accusation is noise; core China e-commerce/cloud thesis intact. Do not sell at these levels.
• FSLR | STRONG HOLD | 7/10 — Securities lawsuits are a headline overhang; core U.S. IRA-tailwind thesis intact. Hold through the noise.
• GOOGL | STRONG HOLD | 8/10 — Down 6.6% since last review but 1Y still +102%. Search + Cloud + Waymo optionality intact.
• ISRG | BUY MORE | 8/10 — Trading $3 above 52W low. Best-in-class surgical robotics; margin/growth profile unchanged. Adding into weakness.
• MKL | HOLD | 7/10 — Modest appreciation toward analyst target. Nothing to do.
• MP | STRONG HOLD | 8/10 — Only Western Hemisphere integrated rare earths play. Strategic asset regardless of near-term price action.
• SYM | HOLD | 6/10 — Warehouse automation thesis intact but stock rangebound. Hold.
• TSLA | HOLD | 5/10 — Down 6.3% since last review. Conviction low; execution risk elevated. No action but not adding.
• UNH | HOLD | 7/10 — At 52W high after +27.7% one-month rally. Thesis re-rated; hold, don't chase.

⚠️ WATCH LIST

• $AVAV (portfolio, 3/10) — Approaching a sell trigger. If the $89M charge is followed by any additional guidance cut or contract loss, this comes out of the book.
• $LLY (watchlist, 5/10) — Watching for either a pullback to ~$1,050 or an orforglipron Phase 3 readout to re-upgrade to 7/10.
• $FCX (recommend, 6/10) — Q2 earnings imminent. Copper thesis + AI infrastructure demand story is the key catalyst. Beat could push to 7/10; guide-down would take conviction lower.
• $PANW (monitoring, 6/10) — Up 19.5% on the week, cybersecurity rally. Valuation now the constraint — watching for a pullback to initiate, not chasing at the top.

🔁 RE-REVIEW QUEUE

• CEG | Was 6/10 | Dropped 2026-05-13 — Utility/nuclear play dropped when higher-conviction names took the slot. With AI power demand narrative intensifying ($VST and $GEV both getting attention), the setup for regulated nuclear may have improved — worth a fresh look.
• DDOG | Was 6/10 | Dropped 2026-05-07 — Observability SaaS dropped on valuation concerns. AI-driven data volume growth is a genuine tailwind; if valuation has compressed, could re-enter.
• TTD | Was 6/10 | Dropped 2026-05-07 — CTV ad-tech leader. Amazon Prime Video ads lawsuit (per today's news) reshapes the CTV competitive dynamic — could be catalyst either way.
• BWXT | Was 6/10 | Dropped 2026-05-07 — Small modular reactor play. Same AI power thesis as CEG — worth revisiting.
• NET | Was 6/10 | Dropped 2026-05-07 — Cloudflare. Edge compute + AI inference story; monitoring for margin improvement.
• KTOS | Was 6/10 | Dropped 2026-05-13 — Defense/drone play. AVAV weakness has changed the sector setup — Kratos may deserve fresh look.
• CRWD | Was 6/10 | Dropped 2026-05-08 — Cybersecurity. Sector rally today ($PANW +19.5%) suggests fresh look warranted.
• NTRA | Was 6/10 | Dropped 2026-05-09 — Diagnostics. No obvious new catalyst but re-review window has arrived.

To run a fresh dive on any of these, ask Meridian in the chat.